{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:08:58Z","timestamp":1792318138657,"version":"4.4.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00325","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T04:56:09Z","timestamp":1589432169000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":75,"title":["Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Ning","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Kang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjian","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.14740\/jocmr2970w","article-title":"Gender disparities in osteoporosis.","volume":"9","author":"Alswat","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","article-title":"Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.","volume":"101","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"B3","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","article-title":"Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.","volume":"8","author":"Anastasilakis","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"B5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women.","volume":"16","author":"Bekker","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/jbmr.2005.20.12.2274","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"B7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis.","volume":"374","author":"Black","year":"2016","journal-title":"New Engl. J. Med."},{"key":"B8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.cbpa.2005.06.011","article-title":"Aptamers as tools for target validation.","volume":"9","author":"Blank","year":"2005","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab.","volume":"51","author":"Body","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/oli.2005.15.183","article-title":"Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues.","volume":"15","author":"Boomer","year":"2005","journal-title":"Oligonucleotides"},{"key":"B12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin. Oral Implants Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.pharmtox.010909.105547","article-title":"Discovery and development of therapeutic aptamers.","volume":"50","author":"Bouchard","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chembiol.2004.10.017","article-title":"Direct in vitro selection of a 2\u2019-O-methyl aptamer to VEGF.","volume":"12","author":"Burmeister","year":"2005","journal-title":"Chem. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","article-title":"RNA-based therapeutics: current progress and future prospects.","volume":"19","author":"Burnett","year":"2012","journal-title":"Chem. Biol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/gerona\/glt093","article-title":"Public health impact of osteoporosis.","volume":"68","author":"Cauley","year":"2013","journal-title":"J. Gerontol. Ser. A"},{"key":"B17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1759720X13483187","article-title":"A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis.","volume":"5","author":"Cianferotti","year":"2013","journal-title":"Ther. Adv. Musculoskel. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.biochi.2012.02.025","article-title":"In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging.","volume":"94","author":"Cibiel","year":"2012","journal-title":"Biochimie"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-010-1272-8","article-title":"New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK\/RANKL axis.","volume":"22","author":"Crockett","year":"2011","journal-title":"Osteoporos. Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"New Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.biotechadv.2015.02.008","article-title":"Current approaches in SELEX: an update to aptamer selection technology.","volume":"33","author":"Darmostuk","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40266-018-0535-5","article-title":"Author correction to: denosumab: a review in postmenopausal osteoporosis.","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs Aging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinthera.2012.02.002","article-title":"Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.","volume":"34","author":"Dempster","year":"2012","journal-title":"Clin. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.rdc.2011.07.004","article-title":"The RANKL pathway and denosumab.","volume":"37","author":"Dore","year":"2011","journal-title":"Rheum. Dis. Clin."},{"key":"B25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/14397595.2017.1308454","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis.","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1172\/JCI17215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"B28","year":"2013","journal-title":"European Medicines Agency. European Public Assessment Report: procedure no."},{"key":"B29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14712598.2018.1401607","article-title":"Monoclonal antibodies for treating osteoporosis.","volume":"18","author":"Faienza","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress.","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporosis. Int."},{"key":"B32","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration.","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-1001-2","article-title":"RANKL\/RANK\/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.","volume":"38","author":"Infante","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2967\/jnumed.114.149484","article-title":"PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer.","volume":"56","author":"Jacobson","year":"2015","journal-title":"J. Nucl. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function.","volume":"26","author":"Jamal","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1902\/jop.2007.070073","article-title":"RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.","volume":"78","author":"Jin","year":"2007","journal-title":"J. Periodontol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.25958","article-title":"Aptamers in the therapeutics and diagnostics pipelines.","volume":"8","author":"Kaur","year":"2018","journal-title":"Theranostics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cbpa.2008.06.028","article-title":"SELEX with modified nucleotides.","volume":"12","author":"Keefe","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL.","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1134\/s000629790713007x","article-title":"Methods for selection of aptamers to protein targets.","volume":"72","author":"Kulbachinskiy","year":"2007","journal-title":"Biochemistry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0092-8674(00)81569-x","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG\u2013RANK\u2013RANKL pathway and the development of denosumab.","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","article-title":"Aptamers: problems, solutions and prospects.","volume":"5","author":"Lakhin","year":"2013","journal-title":"Acta Naturae"},{"key":"B45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jtbi.2004.03.023","article-title":"Modeling the interactions between osteoblast and osteoclast activities in bone remodeling.","volume":"229","author":"Lemaire","year":"2004","journal-title":"J. Theor. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2017.5","article-title":"Olaptesed pegol, an anti-CXCL12\/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed\/refractory multiple myeloma: a Phase IIa Study.","volume":"31","author":"Ludwig","year":"2017","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1039\/c2an15905h","article-title":"Single-stranded DNA (ssDNA) production in DNA aptamer generation.","volume":"137","author":"Marimuthu","year":"2012","journal-title":"Analyst"},{"key":"B48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4161\/mabs.19909","article-title":"The birth pangs of monoclonal antibody therapeutics.","volume":"4","author":"Marks","year":"2012","journal-title":"MAbs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02491-9","article-title":"Strontium-loaded titania nanotube arrays repress osteoclast differentiation through multiple signalling pathways: in vitro and in vivo studies.","volume":"7","author":"Mi","year":"2017","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody.","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Osteoporos. Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates.","volume":"101","author":"Miller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/720504","article-title":"The interplay between the bone and the immune system.","volume":"2013","author":"Mori","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1210\/en.2003-0717","article-title":"Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.","volume":"144","author":"Nakamura","year":"2003","journal-title":"Endocrinology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3109\/13697137.2015.1045484","article-title":"Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.","volume":"18","author":"Palacios","year":"2015","journal-title":"Climacteric"},{"key":"B56","doi-asserted-by":"publisher","first-page":"706","DOI":"10.14348\/molcells.2017.0225","article-title":"Current understanding of RANK signaling in osteoclast differentiation and maturation.","volume":"40","author":"Park","year":"2017","journal-title":"Mol. Cells"},{"key":"B57","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.2174\/1568026615666150413153143","article-title":"Peptide aptamers: development and applications.","volume":"15","author":"Reverdatto","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy.","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Rep."},{"key":"B60","article-title":"Advances and challenges in therapeutic monoclonal antibodies drug development.","volume":"2018","author":"Santos","year":"2018","journal-title":"Braz. J. Pharm. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/11207370-000000000-00000","article-title":"Denosumab.","volume":"71","author":"Scott","year":"2011","journal-title":"Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/gme.0b013e318267f909","article-title":"Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"B63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit.","volume":"3","author":"Sims","year":"2014","journal-title":"Bonekey Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.2147\/OTT.S135867","article-title":"The RANK\/RANKL\/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy.","volume":"10","author":"Sisay","year":"2017","journal-title":"Onco Targets Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat. Genet."},{"key":"B67","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/s120100612","article-title":"Aptamers and their biological applications.","volume":"12","author":"Song","year":"2012","journal-title":"Sensors"},{"key":"B68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis.","volume":"4","author":"S\u00f6zen","year":"2017","journal-title":"Eur. J. Rheumatol."},{"key":"B69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/138161211795049769","article-title":"Advances and perspectives in cell-specific aptamers.","volume":"17","author":"Sun","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/mabi.201100173","article-title":"PEGylated Anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells.","volume":"11","author":"Tan","year":"2011","journal-title":"Macromol. Biosci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"45478","DOI":"10.1038\/srep45478","article-title":"Generation of aptamers from a primer-free randomized ssDNA library using magnetic-assisted rapid aptamer selection.","volume":"7","author":"Tsao","year":"2017","journal-title":"Sci. Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS.","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"B73","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/clpt.2013.58","article-title":"Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.","volume":"94","author":"Vater","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clinthera.2007.09.001","article-title":"Pegaptanib in the treatment of wet, age-related macular degeneration.","volume":"1","author":"Vinores","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL\u2013RANK\u2013OPG system in immunity, bone, and beyond.","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2010.07.007","article-title":"Which fractures are most attributable to osteoporosis?","volume":"64","author":"Warriner","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.addr.2011.10.002","article-title":"Aptamer-conjugated nanomaterials and their applications.","volume":"63","author":"Yang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which opg\/ocif inhibits osteoclastogenesis in vitro.","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.3390\/ijms13033341","article-title":"Generating aptamers by cell-SELEX for applications in molecular medicine.","volume":"13","author":"Ye","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1359\/jbmr.2003.18.4.599","article-title":"Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics.","volume":"18","author":"Zaidi","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/jbmr.2855","article-title":"Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis.","volume":"31","author":"Zebaze","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"B83","first-page":"406","article-title":"Nobiletin acts as a potential anti-cancer agent against osteosarcoma by regulating ERK and AKT signaling pathways.","volume":"9","author":"Zhang","year":"2014","journal-title":"Bangladesh J. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges.","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T04:56:13Z","timestamp":1589432173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":84,"alternative-id":["10.3389\/fcell.2020.00325"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00325","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"article-number":"325"}}